GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: GLYC
- Previous Close: $6.36
- 50 Day Moving Average: $6.12
- 200 Day Moving Average: $6.56
- 52-Week Range: $4.28 - $9.25
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.40
- P/E Growth: 0.00
- Market Cap: $146.69M
- Outstanding Shares: 23,065,000
- Beta: 2.97
- Return on Equity: -78.05%
- Return on Assets: -67.09%
Companies Related to GlycoMimetics:
- Current Ratio: 8.60%
- Quick Ratio: 8.60%
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?
5 brokerages have issued 12 month target prices for GlycoMimetics' stock. Their forecasts range from $11.00 to $16.00. On average, they expect GlycoMimetics' stock price to reach $13.50 in the next year.
When will GlycoMimetics announce their earnings?
GlycoMimetics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about GlycoMimetics stock?
Here are some recent quotes from research analysts about GlycoMimetics stock:
According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (1/17/2017)
Cowen and Company analysts commented, "We also think wholly owned GMI-1271 has generated very promising Ph1/2 data in AML showing chemo potentiation and likely improved response rates to standard of care; followup data from more patients is due 4Q16," analyst Ritu Baral wrote in a note.Glycomimetics' clinical pipeline is currently focused on a class of cell-adhesion molecules called selectins that are central to bone marrow and blood cell adhesion.Related Link: GlycoMimetics Reports Dosing Of First Patient In Phase 2 Trial Of GMI-1271 In Newly Diagnosed AMLBaral continued that these molecules are key to interactions between stem and blood cells and vasculature/bone marrow structural tissues. These selectin antagonists prevent interactions by competitive binding, thereby potentially preventing certain disease-related processes.Rivipansel is currently in a late stage study in Sickle Cell Disease Vaso-Occlusive Crises (SCD VOC) with top-line data due in 2018, and the analyst believes the drug will see almost universal use in SCD crises in the United States with little to no contraindications."As such, we model a per treatment course of $10,000 and model relatively rapid uptake with peak sales of $1 billion in 2023 in US and EU. GLYC will receive low double digit royalties from PFE," (8/15/2016)
Who owns GlycoMimetics stock?
GlycoMimetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (4.34%), Wall Street Associates (0.65%), State Street Corp (0.58%), Renaissance Technologies LLC (0.51%) and Russell Investments Group Ltd. (0.12%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg.
Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?
GlycoMimetics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Franklin Resources Inc..
Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?
GlycoMimetics' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and State Street Corp. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg.
How do I buy GlycoMimetics stock?
Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of GlycoMimetics stock cost?
One share of GlycoMimetics stock can currently be purchased for approximately $6.36.